Cardiac leiomyosarcoma is a malignant mesenchymal neoplasm with smooth muscle differentiation that originates in the heart. It is an extremely rare histological subtype of cardiac sarcoma and poses two closely related diagnostic challenges: demonstrating that the neoplastic cells belong to the smooth muscle lineage and establishing that the tumor is truly primary to the heart. A cardiac lesion may, in fact, also represent spread from a uterine, retroperitoneal, vascular, or other leiomyosarcoma.
The left atrium, particularly the posterior wall and pulmonary vein ostia, is a recurrent site in clinical reports, although right-sided and ventricular locations are also possible. Growth may combine an intracavitary portion capable of obstructing blood flow with a less evident infiltrative component. Defining the disease therefore requires an integrated assessment of histology, anatomy, hemodynamics, and systemic distribution. Treatment is based on collaboration among cardiac surgeons, oncologists, radiologists, and pathologists with sarcoma expertise.
The cell of origin is thought to be a cell capable of smooth muscle differentiation, including cells in vascular walls, although the exact originating cell of an individual tumor often cannot be demonstrated. Proximity to the pulmonary veins makes it especially important to distinguish an atrial mass from a venous tumor extending into the chamber. Advanced infiltration can obliterate the original anatomical relationships; the starting site must therefore be reconstructed by integrating imaging, operative findings, and pathological sampling.
In most patients, no identifiable causal factor is found. The rarity of cardiac leiomyosarcoma precludes attributing specific environmental associations or reliable rates of inherited predisposition to this location. Very young age, multiple tumors, and a suggestive family history may warrant genetic counseling under the general criteria for sarcoma predisposition syndromes. Previous chest irradiation should be documented and evaluated in relation to the radiation field, latency, and tumor features, without automatically assuming causation.
Malignant transformation involves loss of proliferative control, tissue invasion, and the ability to disseminate. As in leiomyosarcomas elsewhere, complex changes affecting cell-cycle regulation and genomic stability pathways may be present; however, cardiac molecular series are too small to establish a unique signature that could independently confirm the diagnosis. Genetic profiling is valuable when it resolves a classification uncertainty or identifies an alteration with documented therapeutic implications.
The mass may be whitish or grayish, nodular or polypoid, with areas of necrosis and hemorrhage. An apparently well-demarcated intracavitary surface does not guarantee a distinct boundary within the wall. Microscopically, intersecting fascicles of spindle cells, eosinophilic cytoplasm, and elongated blunt-ended nuclei are sought; atypia, mitoses, and necrosis support malignancy. Some tumors show marked pleomorphism or less differentiated areas in which recognition of smooth muscle lineage becomes more difficult.
Smooth muscle differentiation is demonstrated by a panel including smooth muscle actin, desmin, and h-caldesmon, interpreted in the context of morphology. Actin alone is insufficiently specific because it may also be expressed by myofibroblastic proliferations and other sarcomas. Marker intensity, distribution, and concordance matter more than the mere presence of positive staining. Loss of a marker in a poorly differentiated area requires adequate sampling and comparison with the rest of the tumor.
Criteria for malignancy must be applied to the neoplasm and anatomical site actually being examined. Combinations of atypia, mitotic activity, and necrosis used for particular categories of uterine smooth muscle tumors are not rules that can be automatically transferred to a cardiac mass. Similarly, hormone receptor expression, when assessed for a relevant indication, must be compared with the gynecological history and any previous specimens: it does not, by itself, establish uterine origin or an indication for endocrine therapy.
The predominant mechanism depends on location. A left atrial mass may obstruct flow through the mitral valve, reduce ventricular preload, and increase atrial pressure. The consequences include pulmonary congestion, postcapillary pulmonary hypertension, and, in more advanced cases, pulmonary edema and low cardiac output. Impairment may be severe even with preserved ventricular contractility because the primary problem concerns ventricular inflow.
Involvement of the pulmonary veins adds an obstruction upstream of the atrium. If involvement is asymmetric, congestion and alveolar hemorrhage may have a regional distribution, with respiratory findings not explained by the mitral gradient alone. Infiltration of the valve apparatus may cause mitral regurgitation and worsen pressure elevation. Mapping the venous relationships therefore clarifies both the symptoms and the feasibility of complete resection.
In right-sided tumors, obstruction of venous return or the tricuspid orifice promotes systemic congestion, edema, and hepatomegaly. Myocardial invasion impairs contraction, compliance, and conduction; coronary involvement may cause ischemia. Pericardial extension may be associated with effusion and tamponade. These effects depend on the extent of the mass and may progress at a different rate from growth measured along a single diameter.
The tumor surface may harbor a thrombus, while friability facilitates detachment of fragments. In the left heart, systemic cerebral, peripheral, or visceral emboli may occur; on the right, embolization affects the pulmonary circulation. Hematogenous metastatic spread is a separate process associated with the ability of tumor cells to colonize other organs. Distinguishing associated thrombosis, tumor embolization, and metastasis is essential to understanding the limits of anticoagulation and local treatment alone.
Dyspnea is common in left-sided obstructive presentations and may be accompanied by orthopnea, cough, or hemoptysis. Palpitations, chest pain, reduced exercise capacity, and syncope reflect different mechanisms that must be investigated. Fatigue, low-grade fever, and weight loss may precede detection of the mass. The initial event is sometimes an embolism or rapidly worsening congestion; in other cases, the lesion is an incidental finding.
The oncological history is particularly important: previous uterine tumors, retroperitoneal masses, vascular neoplasms, and abdominal surgery may change the interpretation of a cardiac lesion. When a muscular tumor was previously diagnosed, direct comparison with the earlier tissue specimens is more informative than the diagnostic name alone in a discharge summary. The chronology should also cover symptom progression, neurological events, hemoptysis, venous thrombosis, and treatments already received.
The physical examination looks for congestion, hypoperfusion, and valvular obstruction. Tachycardia, crackles, murmurs, jugular venous distention, and edema indicate the hemodynamic burden; blood pressure, oxygen saturation, urine output, and mental status help identify deterioration. Peripheral pulses and neurological assessment complete the search for embolic manifestations. Absence of a clear murmur does not rule out severe obstruction, particularly when flow is reduced or the mass changes its relationship with the orifice during the cardiac cycle.
Acute pulmonary edema, shock, tamponade, or an unstable arrhythmia calls for stabilization and prompt decisions about treating the mechanical cause. In these circumstances, the diagnostic sequence focuses on information that will immediately change management. In a stable patient, however, establishing origin and extent before surgery reduces the risk of planning resection as though the lesion were benign.
Echocardiography is the initial examination for visualizing the mass and measuring its effects. Location, attachment, mobility, relationship to the mitral or tricuspid valve, ventricular function, and pericardium are described. Doppler documents obstruction, regurgitation, and estimated pulmonary pressure. Transesophageal imaging may better delineate the posterior atrial wall and venous openings, particularly when transthoracic echocardiography shows only the portion protruding into the chamber.
Cardiac magnetic resonance imaging provides a multiparametric assessment of tissue features and disease extent. Cine sequences show interaction with blood flow and valve behavior; perfusion and late enhancement help identify viable tissue, necrotic areas, and possible adherent thrombus. Signal characteristics vary and are often heterogeneous. Imaging can suggest an infiltrating neoplasm, but definitive differentiation between leiomyosarcoma and other sarcomas requires tissue examination.
Contrast-enhanced cardiothoracic CT helps map the pulmonary veins, cardiac walls, coronary arteries, and mediastinum and evaluate the lungs. In right-sided masses, assessment of the venae cavae and abdominal veins may reveal continuity with an extracardiac lesion. Appropriate acquisition timing helps distinguish an opacification defect from a true mass. The protocol must reflect the anatomical question and renal function; findings obtained using different techniques should not automatically be assigned the same significance.
FDG PET/CT may help detect extracardiac disease or select a biopsy site, while taking physiological myocardial uptake and inflammatory causes into account. Blood tests include a complete blood count and renal and liver assessments; ECG, troponin, and natriuretic peptides are used according to the clinical picture and the cardio-oncology plan. These investigations quantify the consequences and organ reserve, whereas no circulating biomarker can identify cardiac leiomyosarcoma.
Sampling is planned according to mobility, location, embolic risk, and intended treatment. If an accessible extracardiac lesion may represent the same disease, sampling it may yield tissue at lower risk. A left-sided mass requiring urgent resection in any event may be diagnosed on the surgical specimen. Before neoadjuvant therapy, however, a sufficiently reliable classification is needed, obtained through an agreed diagnostic pathway with enough material for morphological and ancillary investigations.
Distinguishing intimal sarcoma is important in atrial and large-vein masses. It may show spindle-cell morphology and expression of some muscle markers; convincing smooth muscle differentiation therefore requires concordance between the immunohistochemical panel and the architecture. MDM2 is investigated when appropriate, distinguishing protein expression from gene amplification. Results must be interpreted in the context of the entire lesion: an isolated positive test cannot replace diagnostic review.
Other alternatives include spindle-cell sarcomas of different lineages, sarcomatoid epithelial neoplasms, and metastatic tumors. Endothelial, epithelial, neural, or skeletal-muscle differentiation markers are added according to the suspected diagnosis. Clinically and radiologically, a myxoma may resemble the intracavitary portion of a leiomyosarcoma; broad posterior attachment, wall invasion, and venous involvement call for a more extensive assessment. Thrombus may also overlap the tumor and change its appearance.
In women with a right-sided mass continuous with the inferior vena cava, intravenous leiomyomatosis should be considered. This histologically benign smooth muscle proliferation can reach the heart and cause dangerous obstruction. It is distinct from leiomyosarcoma, even though the mechanical severity may be comparable. Gynecological history, venous mapping, and histology resolve the question; other smooth muscle proliferations associated with uterine tumors likewise require specialist interpretation rather than classification by cardiac location alone.
A coherent systemic assessment is required to establish a primary cardiac neoplasm. Chest, abdominal, and pelvic CT and targeted investigations of suspicious findings seek both metastases and a possible extracardiac primary. The uterus, retroperitoneum, large vessels, and sites indicated by the history warrant particular attention. A lesion adjoining a pulmonary vein must be described in terms of its anatomical relationships because determining origin may remain uncertain in extensive tumors.
Assessment for metastases considers the lungs and other sites according to symptoms, histology, and initial investigation results. Neurological signs or a specific clinical question warrant brain imaging; the extent of testing in asymptomatic patients is discussed individually. An isolated finding that would radically change treatment intent may require histological confirmation, provided sampling is feasible and the result would affect the decision.
The pathology report documents grade and margins, using the FNCLCC system when applicable and specifying specimen limitations. Resectability is assessed separately: the number of veins involved, longitudinal extension along their walls, ventricular invasion, coronary relationships, and reconstruction options are decisive. Functional status, respiratory and renal reserve, congestion, and arrhythmias are also considered. Size and grade alone cannot describe the complexity of cardiac surgery.
In localized disease, complete resection with microscopically negative margins offers the main prospect of durable local control. It may require removal of atrial wall, venous segments, and valve structures, followed by reconstruction. The surgeon must assess disease beyond the portion protruding into the atrium because simple intracavitary excision may leave infiltrative tissue behind. Orienting the specimen and communicating critical margins to the pathologist make the oncological outcome easier to interpret.
An R1 resection leaves microscopic involvement of a margin; R2 leaves gross residual disease. The feasibility of wider resection depends on the functional cost and the potential for reconstruction. In selected cases, complex techniques, including cardiac autotransplantation, may facilitate access to posterior structures. Debulking surgery may provide relief by removing a hemodynamic obstruction, but this aim must be distinguished from oncological radicality in discussions within the multidisciplinary team and with the patient.
Preoperative treatment may be discussed when the diagnosis is known, the patient is stable, and tumor reduction could improve resection margins. Before starting, the team must define how and when to reassess operability and the safety of blood flow. Critical obstruction often requires prompt mechanical relief because drug response takes time and is uncertain. Following resection, the indication for adjuvant therapy is individualized according to risk, residual disease, and tolerability.
Radiotherapy may be considered for residual disease, recurrence, or an especially high risk of local relapse. Reports of prolonged control after combined treatments support the possibility of benefit in selected patients, but they do not establish a requirement to irradiate every cardiac leiomyosarcoma. Treatment planning, cardiac and respiratory motion, doses to nearby organs, and previous therapies must be considered together, since the tissue requiring protection partly coincides with the organ harboring the malignancy.
Treatment evidence for advanced leiomyosarcoma comes mainly from uterine tumors and extracardiac soft tissue sites. In the randomized LMS-04 trial involving 150 patients with previously untreated metastatic or unresectable disease, doxorubicin and trabectedin followed by trabectedin maintenance improved survival compared with doxorubicin alone: median survival was 33 versus 24 months, with greater toxicity in the combination arm. These results support this option in suitable patients, but trial medians do not describe the individual prognosis of primary cardiac disease or demonstrate efficacy of the same regimen as adjuvant therapy after resection.
Choosing doxorubicin and trabectedin requires assessment of general condition, cardiac and liver function, bone marrow reserve, and capacity for monitoring. Doxorubicin monotherapy remains an option when the balance between expected benefit and tolerability favors less intensive treatment. Adding ifosfamide, used in other sarcoma settings when a rapid response is needed, is not an automatic choice for leiomyosarcoma: histological subtype sensitivity and toxicity burden must guide comparison among regimens.
Later lines of treatment may include trabectedin, regimens containing gemcitabine and docetaxel or dacarbazine, and pazopanib in appropriate settings. Sequencing depends on prior treatments, disease course, and vulnerable organs. Local and systemic responses are evaluated together: a modest reduction in tumor size may improve a critical pressure gradient, whereas a mass stable in size may continue to cause valvular damage or venous congestion.
Endocrine therapy is not a standard treatment for primary cardiac leiomyosarcoma. Isolated receptor expression requires interpretation and comparison with evidence for the specific disease entity, especially when uterine origin is suspected. Similarly, immunotherapy and drugs targeting molecular alterations are considered according to validated biomarkers, relevant indications, or investigational protocols. Broad molecular profiling is most useful when it addresses a concrete clinical question.
Cardioprotection and monitoring are planned before treatment, accounting for both the drugs and damage caused by the tumor. ECG, echocardiography with appropriate functional measurements, and risk-based biomarkers allow comparisons over time; protective measures and any regimen adjustments are decided without separating oncological efficacy from safety. Anticoagulation is indicated for documented thrombus, atrial fibrillation, or other specific conditions and does not prevent detachment of tumor tissue. Nutritional support, symptom control, and integrated palliative care also accompany treatment with active therapeutic intent.
Prognosis is generally poor and depends on local invasion, the possibility of negative margins, metastases, response to treatment, and cardiovascular function. Multiyear remissions after multimodal therapy have been reported, but favorable individual cases are subject to selection and cannot establish a generalizable probability. Historical series are further limited by changes in classification: some diagnoses based on a few markers may be reinterpreted with modern review.
Follow-up must detect cardiac recurrence, extracardiac progression, and late injury. Echocardiography and cardiac MRI are combined according to the structures treated; chest CT and other staging tests are guided by risk and disease course. Assessment considers suspicious tissue as well as venous patency, valve function, and exercise capacity. Recurrent dyspnea, new arrhythmias, or hemoptysis require earlier assessment, even when the most recent oncological evaluation was favorable.
Complications include pulmonary venous obstruction, pulmonary edema, mitral regurgitation, right-sided congestion, embolism, arrhythmias, and tamponade. Distant spread can become the principal clinical determinant even after the cardiac mass is controlled. In left-sided locations, coexisting venous stenosis and mitral obstruction require comprehensive assessment because correcting just one level may leave a major hemodynamic abnormality.
Treatment may leave persistent cardiac dysfunction, reconstruction-related problems, venous stenosis, or arrhythmias even during oncological remission. Chemotherapy and targeted agents add marrow, hepatic, vascular, or myocardial toxicity according to the regimen; radiotherapy can cause late effects on exposed structures. Establishing whether deterioration is due to recurrence, toxicity, or an anatomical sequela enables targeted intervention and retains clinical value even when tumor control is prolonged.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.